Heart drug test for deadly lung pressure disease halted
NCT ID NCT04954742
Summary
This study aimed to see if the drug riociguat could improve the size and function of the right side of the heart in people with two severe types of lung blood pressure disease. It involved 30 adults who were either new to treatment or switching from certain other medications. The trial was terminated early, and its main goal was to measure changes in heart structure over 24 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital
Heidelberg, 69126, Germany
Conditions
Explore the condition pages connected to this study.